$1.14/ day, billed weekly
Cancel anytime

(Ad-Free, Unlimited access)

NO CREDIT CARD REQUIRED

APUS

Apimeds Pharmaceuticals US, Inc. (APUS)

$1.58

Last Close (24-hour delay)

PASS

BUY Advisory
SELL Advisory (Profit)
SELL Advisory (Loss)

Profit
Loss
Pass (Skip investing)

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

08/14/2025: APUS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock

Historic Profit -16.08%

Avg. Invested days 10

Today’s Advisory PASS

Upturn Star Rating

Upturn Advisory Performance

1.0

Stock Returns Performance

1.0

Profits based on simulation

Last Close 08/14/2025

Key Highlights

Company Size ETF	Market Capitalization 0 USD	Price to earnings Ratio -	1Y Target Price -
Price to earnings Ratio -	1Y Target Price -
Volume (30-day avg) -	Beta -	52 Weeks Range 1.37 - 4.00	Updated Date 06/17/2025
52 Weeks Range 1.37 - 4.00	Updated Date 06/17/2025
Dividends yield (FY) -	Basic EPS (TTM) -

Earnings Date

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -	Enterprise Value -	Price to Sales(TTM) -
Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding -	Shares Floating -
Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

About Apimeds Pharmaceuticals US, Inc.

Exchange NYSE MKT	Headquaters Hopewell, NJ, United States
IPO Launch date 2025-05-09	CEO & Director Mr. Erik C. Emerson
Sector Healthcare	Industry Drug Manufacturers - Specialty & Generic	Full time employees 2	Website https://www.apimedsus.com
Full time employees 2	Website https://www.apimedsus.com

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.